Cases & Deals

Celgene files Hatch-Waxman suit against Par Pharmaceutical over generic version of ADHD drug Focalin XR®

Clients Celgene Corporation

Jones Day represents Celgene Corporation in a patent infringement action against Par Pharmaceutical brought pursuant to the Hatch-Waxman Act relating to Celgene’s patented drug Focalin XR®.

Celgene Corporation et al. v. Par Pharmaceutical, Inc., Civil Action No. 2-11-cv-03094 (D.N.J.) (Judge Arleo)

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.